CA2308008A1 - Cassettes d'encapsidation de virus adeno-associe (aav) amplifiable pour la production de vecteurs de aav recombines - Google Patents

Cassettes d'encapsidation de virus adeno-associe (aav) amplifiable pour la production de vecteurs de aav recombines Download PDF

Info

Publication number
CA2308008A1
CA2308008A1 CA002308008A CA2308008A CA2308008A1 CA 2308008 A1 CA2308008 A1 CA 2308008A1 CA 002308008 A CA002308008 A CA 002308008A CA 2308008 A CA2308008 A CA 2308008A CA 2308008 A1 CA2308008 A1 CA 2308008A1
Authority
CA
Canada
Prior art keywords
aav
packaging
rep
gene
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002308008A
Other languages
English (en)
Inventor
Carmel M. Lynch
Haim Burstein
Anthony M. Stepan
Dara H. Lockert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ampliphi Biosciences Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2308008A1 publication Critical patent/CA2308008A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des constructions d'encapsidation d'AAV de haute efficacité ainsi que leurs méthodes d'utilisation. Ces constructions d'encapsidation de haute efficacité comprennent un élément d'activation (tel que la séquence P1 située à l'intérieur du site d'intégration AAV-S1 du chromosome humain 19), lié de manière amplifiable à un ou à un plusieurs gènes d'encapsidation d'AAV. Les constructions peuvent être soit intégrées dans le génome d'une cellule mammifère soit maintenues de manière épisomique. L'utilisation des vecteurs d'encapsidation d'AAV de haute efficacité de l'invention permet la production amplifiable et régulée de constructions de vecteurs de AAVr.
CA002308008A 1997-10-21 1998-10-20 Cassettes d'encapsidation de virus adeno-associe (aav) amplifiable pour la production de vecteurs de aav recombines Abandoned CA2308008A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95523297A 1997-10-21 1997-10-21
US08/955,232 1997-10-21
PCT/US1998/021938 WO1999020779A1 (fr) 1997-10-21 1998-10-20 Cassettes d'encapsidation de virus adeno-associe (aav) amplifiable pour la production de vecteurs de aav recombines

Publications (1)

Publication Number Publication Date
CA2308008A1 true CA2308008A1 (fr) 1999-04-29

Family

ID=25496565

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002308008A Abandoned CA2308008A1 (fr) 1997-10-21 1998-10-20 Cassettes d'encapsidation de virus adeno-associe (aav) amplifiable pour la production de vecteurs de aav recombines

Country Status (5)

Country Link
EP (1) EP1025251A1 (fr)
JP (1) JP2001520051A (fr)
AU (1) AU758541B2 (fr)
CA (1) CA2308008A1 (fr)
WO (1) WO1999020779A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
DE69943129D1 (de) 1998-08-11 2011-02-24 Darwin Discovery Ltd Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs
US6893865B1 (en) * 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
EP1939300A1 (fr) 1999-05-28 2008-07-02 Targeted Genetics Corporation Procédés et compositions pour diminuer le niveau de facteur de nécrose de tumeur (TNF) pour des troubles associés au TNF
US6537540B1 (en) 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
WO2001011034A2 (fr) 1999-08-09 2001-02-15 Targeted Genetics Corporation Vecteurs viraux de recombinaison actives metaboliquement et procede de preparation et d'utilisation de ceux-ci
EP1916258B1 (fr) 1999-08-09 2014-04-23 Targeted Genetics Corporation Améliorations de l'expression d'une séquence de nucléotides hétérologues à brin unique à partir de vecteurs viraux recombinants par la désignation de la séquence de manière à ce qu'elle forme des paires de bases intrabrins
DE10066104A1 (de) * 2000-09-08 2003-01-09 Medigene Ag Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung
ATE405586T1 (de) 2001-05-08 2008-09-15 Darwin Molecular Corp Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
PL3421603T3 (pl) 2009-05-02 2022-02-14 Genzyme Corporation Terapia genowa zaburzeń neurodegeneracyjnych
JP6093358B2 (ja) * 2012-07-06 2017-03-08 タカラバイオ株式会社 アデノ随伴ウイルスベクターの産生細胞

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
AU688428B2 (en) * 1993-11-09 1998-03-12 Johns Hopkins University, The Generation of high titers of recombinant AAV vectors
US6207457B1 (en) * 1995-09-08 2001-03-27 Avigen, Inc. Targeted nucleotide sequence delivery and integration system
EP0850313B8 (fr) * 1995-09-08 2009-07-29 Genzyme Corporation Vecteurs aav ameliores pour la therapie genique
AU1980697A (en) * 1996-03-04 1997-09-22 Targeted Genetics Corporation Methods for transducing cells in blood vessels using recombinant AAV vec tors

Also Published As

Publication number Publication date
AU1096799A (en) 1999-05-10
EP1025251A1 (fr) 2000-08-09
WO1999020779A1 (fr) 1999-04-29
JP2001520051A (ja) 2001-10-30
AU758541B2 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
US6642051B1 (en) Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
US6893865B1 (en) Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
US6541258B2 (en) AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
US6936466B2 (en) Transcriptionally-activated AAV inverted terminal repeats (ITRs) for use with recombinant AAV vectors
US6924128B2 (en) Packaging cell lines for generation of high titers of recombinant AAV vectors
AU707866B2 (en) Packaging cell lines for generation of high titers of recombinant AAV vectors
WO1998027204A9 (fr) Genes d'encapsidation fractionnes de virus adeno-associe (aav) et lignees cellulaires comprenant ces genes utilises pour la production de vecteurs d'aav de recombinaison
CA2269661A1 (fr) Cassettes d'encapsidation d'aav activables par la recombinase servant a la production de vecteurs d'aav
WO1996017947A9 (fr) Lignees cellulaires d'encapsidation utilisees pour la generation de titres hauts de vecteurs aav recombinants
AU758541B2 (en) Amplifiable adeno-associated virus (AAV) packaging cassettes for the production of recombinant AAV vectors
AU749352B2 (en) A conditional replication and expression system
AU1096699A (en) Transcriptionally-activated aav inverted terminal repeats (itrs) for use with recombinant aav vectors
AU2003203790B2 (en) Transcriptionally-activated AAV inverted terminal repeats (ITRs) for use with recombinant AAV vectors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued